Wednesday, August 18, 2010

FDA votes to drop AVASTIN under cost-effectiveness;which treats breast cancer&other cancers;was approved in 2006

This is just another example of the direction our countries health care is moving under the new Obamacare health plan. Sure we can keep our plans...not really an d we will be lucky to get the medical treatment needed to stay alive. I hear under the new health care plan quality of life will be assessed and if they find that it will cost more than $20,000 in six months to keep you alive then it is not cost-effective, thus the treatment won't get approved.

Here is more on the treatment of cancer under Avastin:

Used mainly to treat colon cancer, it was approved by the Food and Drug Administration in 2006 after it was found that by cutting the blood flow to tumors, it helped in treating breast cancer.

An estimated 17,500 American women are treated with the drug each year. It is effective, having been shown to extend life by at least 20 months, but it is not cheap.

Under the new "cost-effectiveness" philosophy of this administration, an FDA advisory panel has voted 12-to-1 to drop the endorsement of Avastin for breast cancer treatment. The FDA usually follows advisory panel recommendations, and a final decision will be announced Sept. 17. If approval of the drug, approved for colon, lung, kidney and brain cancer, is revoked for breast cancer, it is likely that insurers would drop that coverage.

In a joint letter sent to the FDA and key congressional lawmakers last week, Susan Komen of the Cure and the Ovarian Cancer National Alliance (OCNA) urged that Avastin continue to be approved for metastatic breast cancer patients and warned of the message this "decision sends about drug development for women with advanced breast cancer."

AddThis Social Bookmark Button

blog comments powered by Disqus  


Newer Post Older Post Home